ProShares Ultra Nasdaq Biotechnology (BIB)
BIB is a passive ETF by ProShares tracking the investment results of the NASDAQ Biotechnology Index (200%). BIB launched on Apr 7, 2010 and has a 0.95% expense ratio.
ETF Info
US74347R2141
74347R214
Apr 7, 2010
North America (U.S.)
2x
NASDAQ Biotechnology Index (200%)
Multi-Cap
Growth
Expense Ratio
BIB has a high expense ratio of 0.95%, indicating above-average management fees.
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ProShares Ultra Nasdaq Biotechnology, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
ProShares Ultra Nasdaq Biotechnology had a return of -11.72% year-to-date (YTD) and -7.29% in the last 12 months. Over the past 10 years, ProShares Ultra Nasdaq Biotechnology had an annualized return of -5.44%, while the S&P 500 had an annualized return of 10.11%, indicating that ProShares Ultra Nasdaq Biotechnology did not perform as well as the benchmark.
BIB
-11.72%
-11.89%
-27.13%
-7.29%
-6.18%
-5.44%
^GSPC (Benchmark)
-6.06%
-3.27%
-4.87%
9.44%
14.30%
10.11%
Monthly Returns
The table below presents the monthly returns of BIB, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 9.81% | -1.13% | -12.18% | -7.41% | -11.72% | ||||||||
| 2024 | 0.11% | 1.21% | -0.38% | -12.32% | 11.18% | 6.11% | 12.72% | 0.86% | -5.14% | -5.64% | -1.05% | -14.24% | -9.85% |
| 2023 | 6.78% | -13.34% | 1.48% | 2.55% | -5.96% | -0.44% | 1.88% | -1.25% | -8.35% | -13.34% | 9.12% | 25.86% | -1.06% |
| 2022 | -23.24% | -8.09% | 8.39% | -19.39% | -3.68% | 0.44% | 7.92% | -2.99% | -5.90% | 17.27% | 10.93% | -6.89% | -28.85% |
| 2021 | 12.28% | -5.21% | -8.99% | 5.81% | -4.41% | 16.52% | -1.05% | 7.85% | -9.73% | -4.17% | -7.71% | -3.38% | -6.02% |
| 2020 | -11.30% | -0.24% | -15.30% | 30.75% | 16.96% | 2.57% | -3.77% | 1.49% | -1.31% | -7.52% | 22.23% | 9.16% | 39.79% |
| 2019 | 28.42% | 5.11% | -2.34% | -10.24% | -12.21% | 18.57% | -6.48% | -5.86% | -6.81% | 15.47% | 24.01% | 1.40% | 46.71% |
| 2018 | 13.52% | -10.92% | -2.89% | -7.07% | 9.28% | 2.29% | 11.92% | 9.56% | -0.68% | -27.99% | 8.53% | -22.69% | -24.93% |
| 2017 | 9.37% | 13.52% | -2.60% | 2.67% | -8.03% | 17.18% | 5.58% | 8.62% | 0.02% | -11.64% | 0.83% | 2.75% | 40.49% |
| 2016 | -38.93% | -10.03% | 4.07% | 4.82% | 8.10% | -16.15% | 25.88% | -6.16% | 5.62% | -21.71% | 12.60% | -6.58% | -44.17% |
| 2015 | 11.55% | 9.82% | 3.05% | -6.02% | 19.06% | 1.99% | 6.60% | -21.12% | -23.34% | 15.03% | 4.77% | 1.79% | 13.93% |
| 2014 | 17.02% | 14.54% | -20.81% | -6.66% | 8.36% | 14.91% | -5.29% | 21.15% | -2.37% | 16.69% | 5.29% | -1.76% | 66.79% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of BIB is 11, meaning it’s performing worse than 89% of other ETFs on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
ProShares Ultra Nasdaq Biotechnology provided a 2.12% dividend yield over the last twelve months, with an annual payout of $0.95 per share. The fund has been increasing its distributions for 2 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Dividend | $0.95 | $0.85 | $0.04 | $0.02 |
Dividend yield | 2.12% | 1.69% | 0.07% | 0.03% |
Monthly Dividends
The table displays the monthly dividend distributions for ProShares Ultra Nasdaq Biotechnology. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.13 | $0.00 | $0.13 | ||||||||
| 2024 | $0.00 | $0.00 | $0.04 | $0.00 | $0.00 | $0.26 | $0.00 | $0.00 | $0.15 | $0.00 | $0.00 | $0.40 | $0.85 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.04 | $0.04 |
| 2022 | $0.02 | $0.02 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the ProShares Ultra Nasdaq Biotechnology. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ProShares Ultra Nasdaq Biotechnology was 67.24%, occurring on Jun 27, 2016. Recovery took 1152 trading sessions.
The current ProShares Ultra Nasdaq Biotechnology drawdown is 59.23%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -67.24% | Jul 21, 2015 | 237 | Jun 27, 2016 | 1152 | Jan 25, 2021 | 1389 |
| -66.2% | Feb 9, 2021 | 1046 | Apr 8, 2025 | — | — | — |
| -41.44% | May 13, 2011 | 60 | Aug 8, 2011 | 112 | Jan 18, 2012 | 172 |
| -39.01% | Feb 26, 2014 | 33 | Apr 11, 2014 | 114 | Sep 24, 2014 | 147 |
| -36.3% | Apr 16, 2010 | 48 | Jul 1, 2010 | 93 | Dec 17, 2010 | 141 |
Volatility
Volatility Chart
The current ProShares Ultra Nasdaq Biotechnology volatility is 24.42%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.